Vapotherm Inc (NYSE:VAPO) Director Elizabeth H. Weatherman acquired 8,382 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was acquired at an average cost of $11.38 per share, with a total value of $95,387.16.
NYSE:VAPO opened at $8.70 on Thursday. Vapotherm Inc has a 1-year low of $8.30 and a 1-year high of $24.63. The company has a 50-day moving average of $13.80 and a 200 day moving average of $17.74. The firm has a market cap of $166.24 million and a PE ratio of -0.63. The company has a debt-to-equity ratio of 1.42, a current ratio of 5.22 and a quick ratio of 4.34.
Vapotherm (NYSE:VAPO) last released its quarterly earnings data on Monday, July 29th. The company reported ($0.76) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.05. The business had revenue of $11.99 million during the quarter, compared to analysts’ expectations of $11.90 million. Sell-side analysts anticipate that Vapotherm Inc will post -3.07 EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG purchased a new stake in Vapotherm in the fourth quarter worth about $121,000. Marshall Wace North America L.P. purchased a new stake in Vapotherm in the first quarter worth about $161,000. Charles Schwab Investment Management Inc. lifted its stake in Vapotherm by 10.2% in the second quarter. Charles Schwab Investment Management Inc. now owns 12,488 shares of the company’s stock worth $288,000 after acquiring an additional 1,151 shares during the period. Monashee Investment Management LLC purchased a new stake in Vapotherm in the second quarter worth about $484,000. Finally, Arnhold LLC lifted its stake in Vapotherm by 123.9% in the first quarter. Arnhold LLC now owns 25,434 shares of the company’s stock worth $500,000 after acquiring an additional 14,075 shares during the period. 50.85% of the stock is owned by institutional investors.
Vapotherm Company Profile
Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.
Featured Article: Float
Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.